CN1997388A - 粘蛋白状糖蛋白(muc-1)疫苗 - Google Patents
粘蛋白状糖蛋白(muc-1)疫苗 Download PDFInfo
- Publication number
- CN1997388A CN1997388A CNA2005800178997A CN200580017899A CN1997388A CN 1997388 A CN1997388 A CN 1997388A CN A2005800178997 A CNA2005800178997 A CN A2005800178997A CN 200580017899 A CN200580017899 A CN 200580017899A CN 1997388 A CN1997388 A CN 1997388A
- Authority
- CN
- China
- Prior art keywords
- muc
- individuality
- weeks
- treatment
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 title abstract description 48
- 108090000288 Glycoproteins Proteins 0.000 title description 4
- 102000003886 Glycoproteins Human genes 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 72
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims abstract description 71
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims abstract description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 43
- 102100034256 Mucin-1 Human genes 0.000 claims abstract description 17
- 108010008707 Mucin-1 Proteins 0.000 claims abstract 12
- 238000011282 treatment Methods 0.000 claims description 143
- 238000002360 preparation method Methods 0.000 claims description 127
- 239000002502 liposome Substances 0.000 claims description 105
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 75
- 201000001514 prostate carcinoma Diseases 0.000 claims description 58
- 150000002632 lipids Chemical class 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 32
- 229920001184 polypeptide Polymers 0.000 claims description 31
- 230000004083 survival effect Effects 0.000 claims description 31
- 239000002671 adjuvant Substances 0.000 claims description 28
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 27
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 19
- 238000011156 evaluation Methods 0.000 claims description 19
- 238000002347 injection Methods 0.000 claims description 17
- 239000007924 injection Substances 0.000 claims description 17
- 208000024891 symptom Diseases 0.000 claims description 14
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 13
- 229960004397 cyclophosphamide Drugs 0.000 claims description 13
- 238000012360 testing method Methods 0.000 claims description 11
- 230000036541 health Effects 0.000 claims description 9
- 102000000588 Interleukin-2 Human genes 0.000 claims description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 6
- 241000521257 Hydrops Species 0.000 claims description 5
- 206010030113 Oedema Diseases 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 5
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 4
- 208000002151 Pleural effusion Diseases 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 238000010254 subcutaneous injection Methods 0.000 claims description 3
- 239000007929 subcutaneous injection Substances 0.000 claims description 3
- 239000002131 composite material Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 201000007676 prostate small cell carcinoma Diseases 0.000 claims 1
- 208000000649 small cell carcinoma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 abstract description 23
- 239000000203 mixture Substances 0.000 abstract description 19
- 238000009472 formulation Methods 0.000 abstract description 6
- 206010060862 Prostate cancer Diseases 0.000 abstract description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 3
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 63
- 102100038358 Prostate-specific antigen Human genes 0.000 description 63
- 108010062028 L-BLP25 Proteins 0.000 description 35
- 235000001014 amino acid Nutrition 0.000 description 30
- 229940024606 amino acid Drugs 0.000 description 30
- 150000001413 amino acids Chemical class 0.000 description 29
- 201000010099 disease Diseases 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 238000011160 research Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 19
- 238000002560 therapeutic procedure Methods 0.000 description 19
- 230000004927 fusion Effects 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000007717 exclusion Effects 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 11
- 238000012423 maintenance Methods 0.000 description 11
- 230000008859 change Effects 0.000 description 10
- 230000002980 postoperative effect Effects 0.000 description 10
- 238000011471 prostatectomy Methods 0.000 description 10
- 230000003442 weekly effect Effects 0.000 description 10
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 description 8
- 238000002512 chemotherapy Methods 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 230000008685 targeting Effects 0.000 description 8
- 239000000232 Lipid Bilayer Substances 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 6
- 230000002349 favourable effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 208000020816 lung neoplasm Diseases 0.000 description 6
- 210000001370 mediastinum Anatomy 0.000 description 6
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000006866 deterioration Effects 0.000 description 5
- 208000019622 heart disease Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000003018 immunosuppressive agent Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000008093 supporting effect Effects 0.000 description 5
- 239000002691 unilamellar liposome Substances 0.000 description 5
- 208000023275 Autoimmune disease Diseases 0.000 description 4
- 206010061598 Immunodeficiency Diseases 0.000 description 4
- 208000029462 Immunodeficiency disease Diseases 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000003246 corticosteroid Substances 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000007813 immunodeficiency Effects 0.000 description 4
- 229940124589 immunosuppressive drug Drugs 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000009696 proliferative response Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000036642 wellbeing Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 108010063954 Mucins Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 208000009956 adenocarcinoma Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000621 bronchi Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- BPHQZTVXXXJVHI-UHFFFAOYSA-N dimyristoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- -1 palmityl lipid Chemical class 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 210000004224 pleura Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000005730 ADP ribosylation Effects 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241001597008 Nomeidae Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 2
- 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 150000001408 amides Chemical group 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 238000009167 androgen deprivation therapy Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 210000001229 azygos vein Anatomy 0.000 description 2
- 239000005388 borosilicate glass Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 238000011284 combination treatment Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000006251 gamma-carboxylation Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 230000005976 liver dysfunction Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920002704 polyhistidine Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000008085 renal dysfunction Effects 0.000 description 2
- 230000008521 reorganization Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010911 splenectomy Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000019635 sulfation Effects 0.000 description 2
- 238000005670 sulfation reaction Methods 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- HLDJGHAAKRKPAV-QDORLFPLSA-N 2,3,2',3'-tetrakis(3-hydroxytetradecanoyl)-alpha-D-glucosaminyl-1,6-beta-D-glucosamine 1-phosphate Chemical compound O1[C@H](CO)[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 HLDJGHAAKRKPAV-QDORLFPLSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010022095 Injection Site reaction Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 108020004566 Transfer RNA Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 201000010983 breast ductal carcinoma Diseases 0.000 description 1
- 238000013276 bronchoscopy Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000017858 demethylation Effects 0.000 description 1
- 238000010520 demethylation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005315 distribution function Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000015177 dried meat Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000003278 haem Chemical group 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000000568 immunological adjuvant Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-M iodate Chemical compound [O-]I(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-M 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000006122 isoprenylation Effects 0.000 description 1
- 208000003849 large cell carcinoma Diseases 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 238000009099 neoadjuvant therapy Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940059574 pentaerithrityl Drugs 0.000 description 1
- WXZMFSXDPGVJKK-UHFFFAOYSA-N pentaerythritol Chemical compound OCC(CO)(CO)CO WXZMFSXDPGVJKK-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940067626 phosphatidylinositols Drugs 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 238000005222 photoaffinity labeling Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 239000012925 reference material Substances 0.000 description 1
- 201000010174 renal carcinoma Diseases 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000003997 social interaction Effects 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000011255 standard chemotherapy Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000004646 sulfenyl group Chemical group S(*)* 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010809 targeting technique Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 239000000439 tumor marker Substances 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 238000001086 yeast two-hybrid system Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/00117—Mucins, e.g. MUC-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/664—Amides of phosphorus acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
表1:NSCLC研究中的FACT-L生活质量比较 | ||||||
QoL | HIBLRTX | IIIBLRBSC | P | IIIBPE/IV TX | IIIBPE/IVBSC | P |
FACT-L总分数 | ||||||
Δ从基线第19周 | 0.6±12.1 | -7.5±12.7 | .027 | -0.2±13.2 | -8.6±22.2 | .072 |
Δ从基线第31周 | 2.9±14.2 | -8.0±9.0 | .008 | -2.4±10.3 | -0.7±17.0 | .737 |
TOI | ||||||
Δ从基线第19周 | 0.5±8.2 | -6.5±10.9 | .014 | -1.0±10.6 | -6.6±15.0 | .110 |
Δ从基线第31周 | 1.2±10.2 | -6.5±8.3 | .016 | -1.3±8.7 | -2.4±10.5 | .761 |
表2:NSCLC研究的患者特征 | |||
L-BLP25+BSCN=88 | BSCN=83 | 总计N=171 | |
随机选取时的年龄:(岁)中值 | 59.5 | 59 | 59 |
性别:N(%)女性男性 | 36(40.9)52(59.1) | 40(48.2)43(51.8) | 76(44.4)95(55.6) |
ECOG性能状态:N(%)012 | 31(35.2)53(60.2)4(4.5) | 22(26.5)57(68.7)4(4.8) | 53(31.0)110(64.3)8(4.7) |
疾病期:N(%)IIIB LRIIIB MPE或IV | 35(39.8)53(60.2) | 30(36.1)53(63.9) | 65(38)106(62) |
对一线治疗的反应:N(%)稳定的疾病临床反应(PR或CR) | 39(44.3)49(55.7) | 38(45.8)45(54.2) | 77(45.0)94(55.0) |
年龄(岁):n平均值±S.D.中值25%/75%范围 | 1660.4±7.760.054.5/66.046.0至74.0 |
ECOG性能状态:01 | n(%)13(81%)3(19%) |
Gleason等级:678 | 3(19%)10(63%)3(19%) |
受试者编号 | 基线PSA(μg/L) | 第8周PSA(μg/L) | 第8周时的反应 |
001002003004005006007008009010011012013014015016 | 20.0035.000.070.470.170.890.360.580.100.080.590.110.130.711.800.38 | 未达到第8周48.000.070.460.140.940.450.790.110.100.820.180.180.641.900.34 | 未估计进行性稳定的PSA稳定的PSA稳定的PSA稳定的PSA进行性进行性稳定的PSA进行性进行性进行性进行性稳定的PSA稳定的PSA稳定的PSA |
患者ID | 时间间隔APSADT(天) | 时间间隔BPSADT(天) | 时间间隔A和时间间隔B之间的PSADT差异 |
002 | 173 | 476 | 175% |
003 | 133 | 291 | 119% |
004 | 345 | 393 | 14% |
005 | 302 | 342 | 13% |
006 | 172 | 185 | 8% |
007 | 309 | 347 | 12% |
008 | 173 | 332 | 92% |
009 | 404 | 637 | 58% |
010 | 508 | 595 | 17% |
011 | 165 | 257 | 56% |
012 | 241 | 97 | -60% |
013 | 84 | 112 | 33% |
014 | 479 | 844 | 76% |
015 | 227 | 288 | 27% |
016 | 344 | 385 | 12% |
平均值 | 271 | 372 | 44% |
Claims (30)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55813904P | 2004-04-01 | 2004-04-01 | |
US60/558,139 | 2004-04-01 | ||
US57680404P | 2004-06-04 | 2004-06-04 | |
US60/576,804 | 2004-06-04 | ||
PCT/IB2005/002479 WO2005112546A2 (en) | 2004-04-01 | 2005-04-01 | Mucinous glycoprotein (muc-1) vaccine |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410053925.2A Division CN103933556A (zh) | 2004-04-01 | 2005-04-01 | 粘蛋白状糖蛋白(muc-1)疫苗 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1997388A true CN1997388A (zh) | 2007-07-11 |
CN1997388B CN1997388B (zh) | 2014-03-26 |
Family
ID=35428714
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410053925.2A Pending CN103933556A (zh) | 2004-04-01 | 2005-04-01 | 粘蛋白状糖蛋白(muc-1)疫苗 |
CN200580017899.7A Expired - Fee Related CN1997388B (zh) | 2004-04-01 | 2005-04-01 | 粘蛋白状糖蛋白(muc-1)疫苗 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410053925.2A Pending CN103933556A (zh) | 2004-04-01 | 2005-04-01 | 粘蛋白状糖蛋白(muc-1)疫苗 |
Country Status (16)
Country | Link |
---|---|
US (2) | US9173929B2 (zh) |
EP (2) | EP2524700B1 (zh) |
JP (3) | JP5590768B2 (zh) |
CN (2) | CN103933556A (zh) |
AR (1) | AR051350A1 (zh) |
AU (1) | AU2005244675B2 (zh) |
BR (1) | BRPI0509552A (zh) |
CA (1) | CA2562990A1 (zh) |
DK (2) | DK2524700T3 (zh) |
ES (2) | ES2560808T3 (zh) |
HK (1) | HK1109574A1 (zh) |
HU (1) | HUE027378T2 (zh) |
PL (2) | PL2524700T3 (zh) |
PT (2) | PT1737485E (zh) |
TW (2) | TW201204410A (zh) |
WO (1) | WO2005112546A2 (zh) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1377275B1 (en) | 2001-03-27 | 2006-10-25 | Biomira, Inc. | Vaccine for modulating between t1 and t2 immune responses |
CA2482477A1 (en) * | 2002-04-15 | 2003-10-30 | Biomira, Inc. | Synthetic glyco-lipo-peptides as vaccines |
TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
PL1896051T3 (pl) * | 2005-06-28 | 2015-04-30 | Oncothyreon Inc | Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1) |
AU2012268892B2 (en) * | 2005-06-28 | 2016-05-26 | Oncothyreon Inc. | Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine |
US20120039984A1 (en) | 2008-07-03 | 2012-02-16 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
EA020604B1 (ru) * | 2008-12-17 | 2014-12-30 | Онкотиреон, Инк. | Композиция, содержащая липосомы малого размера, и способ ее получения |
WO2011054359A2 (en) | 2009-11-06 | 2011-05-12 | University Of Copenhagen | Method for early detection of cancer |
WO2011133429A1 (en) | 2010-04-19 | 2011-10-27 | Ezose Sciences, Inc | Cancer-related glycopeptide epitopes, antibodies and methods of use |
CA2825972A1 (en) | 2011-02-24 | 2012-08-30 | Oncothyreon Inc. | Muc1 based glycolipopeptide vaccine with adjuvant |
PT3427748T (pt) | 2011-06-24 | 2022-05-03 | Nono Inc | Terapia de combinação para isquemia |
DE102011085695A1 (de) * | 2011-11-03 | 2013-05-08 | Jörg Pohl | Einmalig dosierte Oxazaphosphorine zur Therapie von Krankheiten |
US9241970B2 (en) * | 2011-12-13 | 2016-01-26 | Nono Inc. | Therapy for subarachnoid hemorrhage and ischemia |
CA2912269A1 (en) | 2013-05-14 | 2014-11-20 | Merck Patent Gmbh | Method of treating lung cancer by vaccination with muc-1 lipopeptide |
KR20160043103A (ko) * | 2013-08-21 | 2016-04-20 | 큐어백 아게 | 전립선암 치료를 위한 조성물 및 백신 |
WO2015058831A1 (en) | 2013-10-25 | 2015-04-30 | Merck Patent Gmbh | Elevated biomarker expression in lung cancer patients responding to treatment with muc-1 lipopeptide vaccines |
CN110393797A (zh) * | 2019-05-27 | 2019-11-01 | 南开大学 | 基于糖脂佐剂的糖肽疫苗的制备方法与应用 |
WO2022125956A1 (en) * | 2020-12-11 | 2022-06-16 | Trustees Of Boston University | Immunomodulatory lipopolysaccharide compositions |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US5019383A (en) | 1981-01-09 | 1991-05-28 | New York Blood Center, Inc. | Fatty acid carriers for synthetic peptides |
ZA831547B (en) | 1982-03-15 | 1984-10-31 | New York Blood Center Inc | Fatty acid carriers for synthetic vaccines |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US6090406A (en) | 1984-04-12 | 2000-07-18 | The Liposome Company, Inc. | Potentiation of immune responses with liposomal adjuvants |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5837249A (en) | 1985-04-19 | 1998-11-17 | The Wistar Institute | Method for generating an immunogenic T cell response protective against a virus |
DE3683688D1 (de) | 1985-04-19 | 1992-03-12 | Wistar Inst | Impfstoff fuer die erzeugung einer gegen ein virus schuetzenden immunogenen t-zellen-antwort. |
IT1213029B (it) | 1986-01-30 | 1989-12-07 | Bracco Ind Chimica Spa | Chelati di ioni metallici paramagnetici. |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4868155A (en) | 1987-10-05 | 1989-09-19 | Merck & Co., Inc. | Dipeptidyl 4-0-,6-0-acyl-2-amino-2-deoxy-D-glucose compositions and methods of use in AIDS-immunocompromised human hosts |
ES2085920T3 (es) | 1989-06-23 | 1996-06-16 | Liposome Co Inc | Liposomas dirigidos y metodos de acoplamiento liposoma-proteina. |
US5871746A (en) | 1990-12-18 | 1999-02-16 | Institut National De La Sainte Et De La Recherche Medicale (Inserm) | Cytotoxic T lymphocyte-inducing lipopeptides and use as vaccines |
US5993823A (en) | 1990-12-18 | 1999-11-30 | Institut Pasteur De Lille | Cytotoxic T lymphocyte-inducing lipopeptides and methods of use |
FR2670787B1 (fr) | 1990-12-18 | 1995-06-23 | Pasteur Institut | Lipopeptides inducteurs des lymphocytes t cytotoxiques et utilisation comme vaccins. |
ES2044781B1 (es) | 1992-04-14 | 1994-10-01 | Menarini Lab | Procedimiento para la preparacion de nuevas amidas con accion inhibidora de la fosfolipasa a2 |
WO1993022343A1 (en) | 1992-05-01 | 1993-11-11 | The Rockfeller University | Multiple antigen peptide system having adjuvant properties and vaccines prepared therefrom |
US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
AU2247095A (en) | 1994-04-12 | 1995-10-30 | Biomira Inc. | Cellular immune response-specific antigens and uses therefor |
CA2189356A1 (en) | 1994-05-02 | 1995-11-09 | Ting Chi Wong | Process for preparation of glycosides of tumor-associated carbohydrate antigens |
AU6260796A (en) | 1995-06-07 | 1996-12-30 | National Jewish Center For Immunology And Respiratory Medicine | Isolated formylated bacterial peptides, nucleic acid molecul es and uses thereof |
AUPN568095A0 (en) | 1995-09-27 | 1995-10-26 | Austin Research Institute, The | Anti-Galalpha(1,3)Gal antibody binding peptides |
US5840839A (en) | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
JP2001510440A (ja) * | 1996-03-20 | 2001-07-31 | スローン―ケタリング・インスティテュート・フォー・キャンサー・リサーチ | ムチン接合体ペプチドワクチン |
ATE273320T1 (de) | 1996-04-11 | 2004-08-15 | Univ British Columbia | Fusogene liposomen |
US5910306A (en) | 1996-11-14 | 1999-06-08 | The United States Of America As Represented By The Secretary Of The Army | Transdermal delivery system for antigen |
AU727863B2 (en) | 1997-05-08 | 2001-01-04 | Oncothyreon Inc. | Method for generating activated T-cells and antigen-pulsed antigen-presenting cells |
JPH11139961A (ja) | 1997-11-06 | 1999-05-25 | Taisho Pharmaceut Co Ltd | リポソームの製造方法 |
JP2002509102A (ja) | 1998-01-16 | 2002-03-26 | バイオミラ・ユーエスエイ・インコーポレイテッド | リポマトリックス製剤 |
FR2774687B1 (fr) | 1998-02-06 | 2002-03-22 | Inst Nat Sante Rech Med | Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques |
FR2776926B1 (fr) | 1998-04-07 | 2003-10-24 | Inst Nat Sante Rech Med | Lipopeptides inducteurs de cytotoxicite t lymphocytaire portant au moins un epitope t auxiliaire, et leurs utilisations pour la vaccination |
US6104536A (en) | 1998-09-18 | 2000-08-15 | 3M Innovative Properties Company | High efficiency polarization converter including input and output lenslet arrays |
JP2002529240A (ja) | 1998-11-13 | 2002-09-10 | オプタイム セラピュウティクス, インコーポレイテッド | リポソーム生成のための方法および装置 |
US20020051813A1 (en) * | 1999-01-15 | 2002-05-02 | Lawrence Boni | Lipomatrix preparation |
US7147850B2 (en) | 1999-08-18 | 2006-12-12 | Altarex Medical Corp. | Therapeutic binding agents against MUC-1 antigen and methods for their use |
DE60018761T2 (de) | 1999-08-18 | 2006-02-02 | Altarex Medical Corp., Edmonton | Therapeutischer antikörper gegen das muc-1-antigen und verfahren zu dessen verwendung |
PT1210430E (pt) | 1999-09-08 | 2006-12-29 | Imp Cancer Res Tech | Péptidos derivados de muc-1 |
JP2003514824A (ja) | 1999-11-15 | 2003-04-22 | ビオミラ,インコーポレーテッド | 合成脂質−a類似体およびその使用 |
CA2404327A1 (en) | 2000-03-24 | 2001-09-27 | Biomira, Inc. | Lipopeptide adjuvants |
EP1182210A1 (en) | 2000-08-17 | 2002-02-27 | BASTERT, Gunter, Prof.Dr.med.Dr.h.c. | Epitopes of tumor-associated MUC1 antigen |
EP1203614A1 (de) | 2000-11-03 | 2002-05-08 | Polymun Scientific Immunbiologische Forschung GmbH | Verfahren und Vorrichtung zur Herstellung von Lipidvesikeln |
AU1999802A (en) * | 2000-12-01 | 2002-06-11 | Lawrence Boni | Preparation of large liposomes by infusion into peg |
EP1377275B1 (en) | 2001-03-27 | 2006-10-25 | Biomira, Inc. | Vaccine for modulating between t1 and t2 immune responses |
EP2263465A1 (en) * | 2001-07-06 | 2010-12-22 | Sloan-Kettering Institute for Cancer Research | Polyvalent conjugate vaccine for cancer |
JP3760467B2 (ja) | 2002-04-09 | 2006-03-29 | ソニー株式会社 | コンテンツ再生装置および方法、記録媒体、並びにプログラム |
CA2482477A1 (en) | 2002-04-15 | 2003-10-30 | Biomira, Inc. | Synthetic glyco-lipo-peptides as vaccines |
ATE457733T1 (de) | 2002-05-09 | 2010-03-15 | Oncothyreon Inc | Lipid-a- und andere kohlenhydrat-liganden-analoga |
US20030235610A1 (en) | 2002-06-21 | 2003-12-25 | Piedmont Pharmaceuticals, Llc | Liposomes containing biologically active compounds |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
WO2004071638A2 (en) | 2003-02-11 | 2004-08-26 | Regents Of The University Of California, The | Microfluidic devices and method for controlled viscous shearing and formation of amphiphilic vesicles |
US9198645B2 (en) | 2003-11-26 | 2015-12-01 | The United States of America, as represented by the Secretary of Commerce of The National Institute of Standards and Technology | Controlled vesicle self-assembly in continuous two phase flow microfluidic channels |
TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
PL1896051T3 (pl) | 2005-06-28 | 2015-04-30 | Oncothyreon Inc | Sposób leczenia pacjentów szczepionką glikoproteiny mucynowej (muc-1) |
US9005654B2 (en) | 2005-07-27 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Systems and methods for manufacturing liposomes |
JP5126874B2 (ja) | 2007-05-21 | 2013-01-23 | 国立大学法人神戸大学 | リポソーム製剤の製造方法 |
EA020604B1 (ru) | 2008-12-17 | 2014-12-30 | Онкотиреон, Инк. | Композиция, содержащая липосомы малого размера, и способ ее получения |
-
2005
- 2005-03-31 TW TW100134756A patent/TW201204410A/zh unknown
- 2005-03-31 TW TW094110256A patent/TWI395591B/zh not_active IP Right Cessation
- 2005-04-01 PL PL11196228T patent/PL2524700T3/pl unknown
- 2005-04-01 CN CN201410053925.2A patent/CN103933556A/zh active Pending
- 2005-04-01 HU HUE11196228A patent/HUE027378T2/en unknown
- 2005-04-01 PL PL05769609T patent/PL1737485T3/pl unknown
- 2005-04-01 US US10/594,992 patent/US9173929B2/en not_active Expired - Fee Related
- 2005-04-01 DK DK11196228.8T patent/DK2524700T3/en active
- 2005-04-01 AR ARP050101311A patent/AR051350A1/es not_active Application Discontinuation
- 2005-04-01 WO PCT/IB2005/002479 patent/WO2005112546A2/en active Application Filing
- 2005-04-01 DK DK05769609.8T patent/DK1737485T3/da active
- 2005-04-01 EP EP11196228.8A patent/EP2524700B1/en active Active
- 2005-04-01 AU AU2005244675A patent/AU2005244675B2/en not_active Ceased
- 2005-04-01 PT PT57696098T patent/PT1737485E/pt unknown
- 2005-04-01 BR BRPI0509552-2A patent/BRPI0509552A/pt not_active IP Right Cessation
- 2005-04-01 JP JP2007505675A patent/JP5590768B2/ja not_active Expired - Fee Related
- 2005-04-01 ES ES11196228.8T patent/ES2560808T3/es active Active
- 2005-04-01 CA CA002562990A patent/CA2562990A1/en not_active Abandoned
- 2005-04-01 CN CN200580017899.7A patent/CN1997388B/zh not_active Expired - Fee Related
- 2005-04-01 ES ES05769609.8T patent/ES2478006T3/es active Active
- 2005-04-01 PT PT111962288T patent/PT2524700E/pt unknown
- 2005-04-01 EP EP05769609.8A patent/EP1737485B1/en active Active
-
2008
- 2008-01-10 HK HK08100332.9A patent/HK1109574A1/zh not_active IP Right Cessation
-
2011
- 2011-11-04 JP JP2011242039A patent/JP5868125B2/ja not_active Expired - Fee Related
-
2014
- 2014-05-15 JP JP2014101006A patent/JP2014177479A/ja active Pending
-
2015
- 2015-09-25 US US14/866,420 patent/US20160082093A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1997388B (zh) | 粘蛋白状糖蛋白(muc-1)疫苗 | |
US9119784B2 (en) | Method of treating patients with a mucinous glycoprotein (MUC-1) vaccine | |
AU2012268892B2 (en) | Method of Treating Patients with a Mucinous Glycoprotein (MUC-1) Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1109574 Country of ref document: HK |
|
ASS | Succession or assignment of patent right |
Owner name: CANCER PREVENTION CANADA CO., LTD. Free format text: FORMER OWNER: BIOMIRA CO., LTD. Effective date: 20100329 Owner name: CANCER PREVENTION CO., LTD. Free format text: FORMER OWNER: CANCER PREVENTION CANADA CO., LTD. Effective date: 20100329 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: ALBERTA PROVINCE, CANADA TO: WASHINGTON, U.S.A. |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20100329 Address after: Washington State Applicant after: ONCOTHYREON Inc. Address before: alberta canada Applicant before: Cancer protection Canada Co. Effective date of registration: 20100329 Address after: alberta canada Applicant after: Cancer protection Canada Co. Address before: alberta canada Applicant before: Biomila |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1109574 Country of ref document: HK |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 Termination date: 20170401 |